Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer

Breast Cancer Research and Treatment

Volumn 127, Issue 2, 2011, Pages 429-438

  Coleman, R ^a   Woodward, E ^a,b   Brown, J ^a,b   Cameron, D ^b,c   Bell, R ^d   Dodwell, D ^b   Keane, M ^e   Gil, M ^f   Davies, C ^b   Burkinshaw, R ^a   Houston, S J ^g   Grieve, R J ^h   Barrett Lee, P J ⁱ   Thorpe, H ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Andrew Love Cancer Centre   (Australia)

^e UNIVERSITY HOSPITAL GALWAY   (Ireland)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^h UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

ⁱ VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

Adjuvant therapy; Breast cancer; Osteonecrosis of the jaw; Safety; Zoledronic acid

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

ALOPECIA; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHEST INFECTION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; INDIGESTION; INFECTION; IRITIS; JAW OSTEONECROSIS; KIDNEY FAILURE; LETHARGY; LOWER RESPIRATORY TRACT INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MASTITIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; STOMATITIS; TASTE DISORDER; THORAX PAIN; THROMBOEMBOLISM; TOOTH DISEASE; TRANSIENT ISCHEMIC ATTACK; VOMITING; WOUND INFECTION;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; JAW DISEASES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; OSTEONECROSIS; TREATMENT OUTCOME;

EID: 79958182699     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1429-y     Document Type: Article

References (31)

1. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN2002: cancer incidence, mortality and prevalence worldwide. IARCpress, Lyon [06/01/2010]. Available from: http://www-dep.iarc.fr/
2. JR Benson I Jatoi M Keisch FJ Esteva A Makris VC Jordan 2009 Early breast cancer Lancet 373 1463 1479 19394537 10.1016/S0140-6736(09)60316-0
3. PD Ottewell H Monkkonen M Jones DV Lefley RE Coleman I Holen 2008 Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer J Natl Cancer Inst 100 1167 1178 18695136 10.1093/jnci/djn240 1:CAS:528:DC%2BD1cXhtFKrsb7J
4. HL Neville-Webbe A Rostami-Hodjegan CA Evans RE Coleman I Holen 2005 Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells Int J Cancer 113 364 371 15455384 10.1002/ijc.20602 1:CAS:528:DC%2BD2MXhsFSq (Pubitemid 40038702)
5. M Gnant B Mlineritsch W Schippinger G Luschin-Ebengreuth S Postlberger C Menzel, et al. 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 679 691 19213681 10.1056/NEJMoa0806285 1:CAS:528:DC%2BD1MXhvVyisbk%3D
6. MA Perazella GS Markowitz 2008 Bisphosphonate nephrotoxicity Kidney Int 74 1385 1393 18685574 10.1038/ki.2008.356 1:CAS:528:DC%2BD1cXhtlOjtrrJ
7. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas, et al. 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587 16314620 10.1200/JCO.2005.02.8670 (Pubitemid 46211499)
8. S Khosla D Burr J Cauley DW Dempster PR Ebeling D Felsenberg, et al. 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 1479 1491 17663640 10.1359/jbmr.0707onj (Pubitemid 351229318)
9. Cancer therapy evaluation program common toxicity criteria, version 2.0. DCTD, NCI, NIH, DHHS
10. RE Marx 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic J Oral Maxillofac Surg 61 1115 1117 12966493 10.1016/S0278-2391(03)00720-1 (Pubitemid 37064711)
11. SL Ruggiero TB Dodson LA Assael R Landesberg RE Marx B Mehrotra 2009 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update J Oral Maxillofac Surg 67 Supplement 1 2 12 19371809
12. A Brufsky WG Harker JT Beck R Carroll E Tan-Chiu C Seidler, et al. 2007 Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 25 829 836 17159193 10.1200/JCO.2005.05.3744 1:CAS:528:DC%2BD2sXjvVKmtL0%3D (Pubitemid 350002883)
13. H Eidtmann R de Boer N Bundred A Llombart N Davidson P Neven G von Minckwitz J Miller N Schenk R Coleman 2010 Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study Ann Oncol 21 2188 2194 20444845 10.1093/annonc/mdq217 1:STN:280:DC%2BC3cbhsVSjtw%3D%3D
14. N Schenk A Lombart A Frassoladti P Neven G Jerusalem I Deleu, et al. 2007 The E-ZO-FAST trial: zoledronic acid (ZOL) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) Eur J Cancer 5 suppl 186 187 9abs
15. R Coleman R Burkinshaw M Winter H Neville-Webbe J Lester E Woodward J Brown 2011 Zoledronic acid Expert Opin Drug Saf 10 1 133 145 21114419 10.1517/14740338.2011.540387 1:CAS:528:DC%2BC3cXhsFOjsbvJ
16. Stopeck A (2009) A comparison of denosumab versus zoledronic acid on the incidence of skeletal-related events in breast cancer patients with bone metastases. Cancer Research, 69(24): San Antonio breast cancer conference presentation Abs 22
17. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181-188
18. T Fehm V Beck M Banys HP Lipp M Hairass S Reinert, et al. 2009 Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynaecological malignancies Gynecol Oncol 112 605 609 19136147 10.1016/j.ygyno.2008.11.029 1:CAS:528: DC%2BD1MXisVOhsr0%3D
19. C Walter B Al-Nawas Ad Bois L Buch P Harter KA Grötz 2009 Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients Cancer 115 1631 1637 19156913 10.1002/cncr.24119 1:CAS:528:DC%2BD1MXltVOntLg%3D
20. RE Coleman 2008 Risks and benefits of bisphosphonates Br J Cancer 98 1736 1740 18506174 10.1038/sj.bjc.6604382 1:CAS:528:DC%2BD1cXmtlCis7c%3D (Pubitemid 351748847)
21. A Munier V Gras M Andrejak N Bernard M-J Jean-Pastor S Gautier, et al. 2005 Zoledronic acid and renal toxicity: data from French adverse effect reporting database Ann Pharmacother 39 7 1194 1197 15956222 10.1345/aph.1E589 1:CAS:528:DC%2BD2MXms12hu7c%3D (Pubitemid 40943168)
22. DM Black PD Delmas R Eastell IR Reid S Boonen JA Cauley, et al. 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822 17476007 10.1056/NEJMoa067312 1:CAS:528:DC%2BD2sXltVSktLc%3D (Pubitemid 46698462)
23. DH Solomon L Rekedal SM Cadarette 2009 Osteoporosis treatments and adverse events Curr Opin Rheumatol 21 363 368 19412101 10.1097/BOR. 0b013e32832ca433
24. TJ Bunch JL Anderson HT May JB Muhlestein BD Horne BG Crandall, et al. 2009 Relation of bisphosphonate therapies and risk of developing atrial fibrillation Am J Cardiol 103 824 828 19268739 10.1016/j.amjcard.2008.11.037 1:CAS:528:DC%2BD1MXisl2rtrY%3D
25. GS Wilkinson J Baillargeon YF Kuo JL Freeman JS Goodwin 2010 Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer J Clin Oncol 28 33 4898 4905 20940190 10.1200/JCO.2010.28.7524 1:CAS:528:DC%2BC3MXisFCnsA%3D%3D
26. N Patlas G Golomb P Yaffe T Pinto E Breuer A Ornoy 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats Teratology 60 68 73 10440778 10.1002/(SICI)1096-9926(199908)60:2<68:: AID-TERA10>3.0.CO;2-H 1:CAS:528:DyaK1MXltFGgt70%3D (Pubitemid 29397194)
27. CF Munns F Rauch L Ward FH Glorieux 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases J Bone Miner Res 19 1742 1745 15355570 10.1359/JBMR.040711 (Pubitemid 41094338)
28. TM Illidge M Hussey CW Godden 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate Clin Oncol 8 257 258 10.1016/S0936-6555(05)80667-3 1:STN:280:DyaK2s%2FisVOrsA%3D%3D (Pubitemid 26335991)
29. S Levy I Fayez N Taguchi J-Y Han J Aiello D Matsui, et al. 2009 Pregnancy outcome following in utero exposure to bisphosphonates Bone 44 428 430 19059370 10.1016/j.bone.2008.11.001 1:CAS:528:DC%2BD1MXhvF2qsbw%3D
30. A Ornoy R Wajnberg O Diav-Citrin 2006 The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment Reprod Toxicol 22 578 579 16996245 10.1016/j.reprotox.2006.05.009 1:CAS:528:DC%2BD28XhtVyitrjI (Pubitemid 44548327)
31. JE Brown SP Ellis JE Lester S Gutcher T Khanna OP Purohit, et al. 2007 Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid Clin Cancer Res 13 5406 5410 17875770 10.1158/1078-0432.CCR-07-0247 1:CAS:528:DC%2BD2sXhtVCitLzI (Pubitemid 47510367)